Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DVAP-Exo + mitoxantrone + siRNA targeting Notch1
- Development stage
- Preclinical
- Lead developer
- Shenyang Pharmaceutical University
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
DVAP-Exo + mitoxantrone + siRNA targeting Notch1 is an experimental injectable therapeutic platform designed to prevent the postoperative recurrence of glioblastoma multiforme (GBM). The platform utilizes GIC-targeting exosomes (DVAP-Exo) modified with the DVAP peptide to specifically target GRP78-positive glioma-initiating cells (GICs). These exosomes serve as a delivery vehicle for two therapeutic cargoes: mitoxantrone (MIT), a cytotoxic small molecule that kills residual glioma cells and GICs, and a small interfering RNA (siRNA) targeting the Notch1 signaling pathway. By silencing Notch1, the therapy aims to reduce the stemness and self-renewal capacity of GICs, which are primarily responsible for tumor recurrence and chemoresistance. This combination approach targets both the bulk tumor cells and the underlying cancer stem cell population within the brain's tumor microenvironment following surgical resection.
- Other names
- DVAP-Exo + MIT + siRNA targeting Notch1DVAP-Exo/MIT/siRNA-Notch1
02
Targets
TOP2A (DNA topoisomerase II)DNANOTCH (Neurogenic locus notch homolog protein 3)APEX1 (DNA-apurinic apyrimidinic site lyase)
Beyond the preview
Go deeper on DVAP-Exo + mitoxantrone + siRNA targeting Notch1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DVAP-Exo + mitoxantrone + siRNA targeting Notch1.